CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Sep. 29, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	[1]	$ 2,785	$ 1,139	[2]
Short-term investments	[1]	6,302	17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019—$541; 2018—$541	[1]	9,439	8,025
Inventories	[1],[3]	8,222	7,508
Current tax assets	[1]	3,730	3,374
Other current assets	[1]	2,954	2,461
Assets held for sale	[1]	29	9,725
Total current assets	[1]	33,459	49,926
Equity-method investments	[1]	15,999	181
Long-term investments	[1]	2,723	2,586
Property, plant and equipment, less accumulated depreciation: 2019—$16,728; 2018—$16,591	[1]	13,701	13,385
Identifiable intangible assets, less accumulated amortization	[1],[4],[5]	38,995	35,211
Goodwill	[1]	58,665	53,411
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,984	1,924
Other noncurrent assets	[1]	4,920	2,799
Total assets	[1]	170,446	159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019—$2,431; 2018—$4,776	[1]	16,617	8,831
Trade accounts payable	[1]	3,942	4,674
Dividends payable	[1]	1,992	2,047
Income taxes payable	[1]	1,892	1,265
Accrued compensation and related items	[1]	2,369	2,397
Other current liabilities	[1]	10,160	10,753
Liabilities held for sale	[1]	0	1,890
Total current liabilities	[1]	36,974	31,858
Long-term debt	[1]	36,044	32,909
Pension benefit obligations, net	[1]	5,103	5,272
Postretirement benefit obligations, net	[1]	1,321	1,338
Noncurrent deferred tax liabilities	[1]	6,724	3,700
Other taxes payable	[1]	12,504	14,737
Other noncurrent liabilities	[1]	6,381	5,850
Total liabilities	[1]	105,051	95,664
Commitments and Contingencies	[1]
Preferred stock	[1]	18	19
Common stock	[1]	468	467
Additional paid-in capital	[1]	87,099	86,253
Treasury stock	[1]	(110,795)	(101,610)
Retained earnings	[1]	100,113	89,554
Accumulated other comprehensive loss	[1]	(11,801)	(11,275)
Total Pfizer Inc. shareholders’ equity	[1]	65,103	63,407
Equity attributable to noncontrolling interests	[1]	293	351
Total equity	[1],[6]	65,396	63,758
Total liabilities and equity	[1]	$ 170,446	$ 159,422

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] The change from December 31, 2018 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see Note 2C).

[4] The increase in Identifiable intangible assets, less accumulated amortization, is primarily due to additions noted in (a) above, partially offset by amortization and intangible asset impairment charges. See Note 4 for additional information on intangible asset impairments.

[5] The increase in the gross carrying amount of Identifiable intangible assets primarily reflects the impact of the acquisition of Array, including the addition of $1.8 billion of Developed technology rights, $340 million of finite-lived Licensing agreements, $4.0 billion of IPR&D and $1.1 billion of indefinite-lived Licensing agreements (see Note 2A).

[6] Amounts may not add due to rounding.